Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Declines By 34.6%
by Renee Jackson · The Cerbat GemVivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 25,097 shares, a drop of 34.6% from the November 30th total of 38,358 shares. Based on an average trading volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the shares of the stock are short sold. Currently, 1.0% of the shares of the stock are short sold. Based on an average trading volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days.
VivoSim Labs Trading Down 6.0%
Shares of VIVS stock opened at $1.89 on Tuesday. The company has a market capitalization of $4.93 million, a price-to-earnings ratio of -0.43 and a beta of 1.27. The firm has a 50-day moving average price of $2.21 and a 200 day moving average price of $2.30. VivoSim Labs has a twelve month low of $1.41 and a twelve month high of $21.96.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. VivoSim Labs had a negative return on equity of 28.83% and a negative net margin of 1,413.57%.
Institutional Investors Weigh In On VivoSim Labs
A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Report on VivoSim Labs
VivoSim Labs Company Profile
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.